Susquehanna International Group’s Indaptus Therapeutics INDP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-637
Closed -$15K 12939
2024
Q4
$15K Buy
+637
New +$20.2K ﹤0.01% 11947
2023
Q1
Sell
-518
Closed -$20.9K 13009
2022
Q4
$20.9K Buy
+518
New +$26.2K ﹤0.01% 11752
2020
Q4
Sell
-38
Closed -$16.6K 11351
2020
Q3
$21K Sell
38
-3
-7% -$2.21K ﹤0.01% 10374
2020
Q2
$26K Sell
41
-7
-15% -$4.33K ﹤0.01% 9885
2020
Q1
$20K Buy
48
+40
+500% +$30.2K ﹤0.01% 9937
2019
Q4
$9K Sell
8
-1
-11% -$1.38K ﹤0.01% 9553
2019
Q3
$15K Buy
+9
New +$26.8K ﹤0.01% 9980
2019
Q2
Sell
-78
Closed -$984K 10514
2019
Q1
$1.28M Buy
78
+55
+239% +$963K ﹤0.01% 4534
2018
Q4
$381K Buy
23
+16
+229% +$218K ﹤0.01% 6552
2018
Q3
$89K Buy
+7
New +$66.5K ﹤0.01% 8648
2018
Q2
Sell
-12
Closed -$173K 9973
2018
Q1
$173K Buy
+12
New +$170K ﹤0.01% 8431

Other funds holding INDP

Susquehanna International Group's INDP Position: Q1 2025 in Review

Susquehanna International Group sold out of Indaptus Therapeutics (INDP) in Q1 2025, closing a stake of 637 shares — an estimated $15K sold.

Susquehanna International Group first reported a position in INDP in Q1 2018 and held it in 11 quarters. The position peaked at $1.28M in Q1 2019. 17 funds tracked by Wall St. Rank hold INDP as of Q1 2025.

  • Susquehanna International Group reported no remaining Indaptus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 637 Indaptus Therapeutics shares in Q1 2025, an estimated $15K.
  • Susquehanna International Group first reported a position in Indaptus Therapeutics in Q1 2018 and held it in 11 quarters.
  • Susquehanna International Group's Indaptus Therapeutics position peaked at $1.28M in Q1 2019.
  • 17 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.